Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study-Reference-Cited by-同舟云学术

Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study

Published:2021 Issue: Volume:29 Page:100496
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

A Kartolo,H Shah,W Hopman,AS Fung,P Wheatley-Price,A Robinson

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Durvalumab after chemoradiotherapy in stage III Non-small cell lung cancer;Antonia;N. Eng. J. Med,2017

2. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N. Eng. J. Med,2018

3. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC – an update from the PACIFIC trial;Faivre-Finn;J. Thor. Oncol,2021

4. Cancer Care Ontario. Drug formulary: durvalumab. https://www.cancercareontario.ca/en/drugformulary/drugs/durvalumab. Date accessed March 24th, 2021.

5. National Comprehensive Cancer Network. Non-small cell lung cancer (version 4.2021). https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Date accessed March 24th, 2021.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

2. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study;Clinical Lung Cancer;2024-06

3. Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis;Oncology Letters;2024-04-03

4. Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy;International Journal of Clinical Oncology;2023-11-30

5. Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis;eClinicalMedicine;2023-10